An observational study in Pulmonary Complications, Cardiovascular Complications and Renal Complications, sponsored by Hellenic Institute for the Study of Sepsis. Recruiting at 6 sites in Greece. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-11-17.
Sponsored by Hellenic Institute for the Study of Sepsis · Observational
More than 660 million cases of COVID-19 have been reported worldwide, with 183 million cases in the EU alone. In several people, after recovery, the effects of the first waves of COVID-19 persisted beyond the acute phase and increased the risk of chronic multiorgan symptoms and disease. Up to 70% of people affected by COVID-19 showed reduced organ function even four months or more after COVID-19 diagnosis. Such a functional decline is associated with an increased risk of the development of non-communicable diseases (NCDs). Thus, there is an essential need for a better knowledge, tools, clinical guidelines and recommendations that it will make it possible to reduce this overrepresentation of NCDs as a consequence of the post-acute phase (PAP) of COVID-19.
The overall concept underpinning "POINT" is to i) build detailed knowledge on the link between the PAP of COVID-19 caused by previous, current, and future SARS-CoV-2 variants in vaccinated and unvaccinated people, and NCDs, ii) identify robust biomarkers and build predictive tools that help early identification and management of risk of NCDs, and iii) develop guidelines and recommendations for all parts of the healthcare value chain, allowing best prevention and care acknowledging vulnerability. The investigators will focus on the NCDs affecting pulmonary, cardiovascular and renal systems.
Post-acute phase of COVID and Non-communicable diseases
Following the emergence of SARS-CoV-2, more than 660 million cases of COVID-19 have been reported worldwide, with 183 million cases in the EU alone. These numbers will continue to grow even after the disease becomes endemic. In some people, after recovery, the effects of the first waves of COVID-19 persisted beyond the acute phase and increased the risk of chronic multiorgan symptoms and disease. Up to 70% of people affected by COVID-19 showed reduced organ function even four months or more after COVID-19 diagnosis. Such a functional decline is associated with an increased risk of the development of non-communicable diseases (NCDs). This is especially true for individuals aged 65 and older as the risk of NCDs increases with age.
Diseases of the pulmonary, cardiovascular, and renal systems are the three major NCDs carrying the most significant burden for the individual as well as society. Studies have documented compromised function of these 3 organ systems in the PAP of COVID-19 in 30%-70% of patients, regardless of the severity of the acute-phase. As homeostasis of these three organs depends on interorgan communication with each other, the impact of PAP of COVID-19 on one will impact the others. The added stress of the PAP of COVID-19 increases the risk of a higher incidence and/or the risk of an accelerated progression of disease.
The prevalence and socioeconomic cost of the three NCDs is already extremely high. Without a strong focus on minimmising the increased risk of incidence and accelerated progression of the NCDs as a result of the PAP of COVID-19, up to 9 million Europeans may be affected and result in an added direct attributable cost of between 19.564 € - 31.064 € per year for each person who develop an NCD.
Beyond state of the art: pulmonary, cardiovascular and renal complications after the PAP of COVID-19
Post-acute COVID-19 and pulmonary complications - Respiratory conditions have been reported as occurring twice as often after severe COVID-19 as in the general population. In a study of 135 individuals, the incidence of impaired lung diffusing capacity (DLCO) and persistent lung damage was demonstrated in 30% of patients 12 months after acute COVID-19. In another study of 142 individuals, pulmonary abnormalities were observed by CT scans in 54% of individuals a year after acute COVID-19.
Post-acute COVID-19 and cardiovascular complications - The PAP of COVID-19 is associated with an increased risk of deep vein thrombosis up to three months after COVID-19 infection, pulmonary embolism up to six months, and a bleeding event up to two months. In a registry study of 153,760 individuals with COVID-19, the 12 month period following the acute phase was characterized by an increased risk and an excess disease burden of cardiovascular diseases, including heart failure, dysrhythmias and stroke. The risks were evident regardless of age, race, sex, and other cardiovascular risk factors. MRI revealed cardiac impairment in 78% of 100 individuals in the PAP of COVID-19.
Post-acute COVID-19 and renal complications - A study of 1733 individuals documented reduced renal function in 35% 6 months after the acute phase of COVID-19 and 13% of patients who did not have acute kidney injury (AKI) during the acute phase showed a disproportionate reduction in renal function during follow-up. A study including \>89,000 individuals revealed an increased risk of adverse renal outcomes in the PAP of COVID-19.
The main unmet needs requiring action at the European level There is an urgent need to enable a better understanding of the causality between PAP of COVID-19 and the increased risk of pulmonary, cardiovascular, and renal complications and thereby an increased risk of onset of disease or aggravation of existing disease. Even though recent studies suggest such a link, there is a need for a more nuanced study of the correlation on much larger cohorts to determine the incidence and risk ratio more accurately. Furthermore, there is a need to compare the outcomes between the early, present, and potential future strains of SARS-CoV-2 variants responsible for the disease. An increased cohort size will also allow a better understanding of the impact of socioeconomic status, difference between sexes, the compounding effects of genotype, pre-existing comorbidities, and use of prescription drugs and of differences between the PAP of early strains of SARS-CoV-2 in mostly unvaccinated individuals compared with current strains in mostly vaccinated people. As this knowledge is currently incomplete, there is an immediate risk that a large part of the European population will not receive optimal and timely care.
Thus far, investigators have concluded that the functional decline of organs caused by COVID-19 cannot be explained by known risk factors. A review of the recent literature suggests that the PAP of COVID-19 is associated with immune dysregulation, elevated levels of autoantibodies, microbiota disruption and clotting and endothelial abnormalities. However, the same review also concludes that the current understanding is not sufficient to improve outcomes and calls for additional research. This underscores the involvement of unidentified molecular mechanisms responsible for the aetiology. A lack of understanding of these inhibits the development of effective biomarkers and drug candidates that allow optimal prediction of the prognosis and treatment of patients following resolution of the initial symptoms of COVID-19.
There is an urgent need for updated clinical practice guidelines and new tools to diagnose and prevent the development and aggravation of NCDs caused by the PAP of COVID-19. Currently, there are very few clinical guidelines and recommendations related to the PAP of COVID-19 and NCDs in general, and there are even fewer clinical guidelines and recommendations that focus on the effects of the PAP of COVID-19 on pulmonary, cardiovascular, and renal health. Modern clinical practice guidelines and recommendations that efficiently bridge the gap between research and current practice are invaluable for securing best quality of care, patient outcomes and cost effectiveness. Unfortunately, the development of a guideline or a recommendation does not necessarily lead to changes in clinical practice. Clinical guidelines and recommendations are not always followed, and it is estimated that approximately 30%-40% of patients receive treatment that is not based on scientific evidence and 20%-25% receive treatments that are not needed or potentially harmful.
7,990 studies on the registry are indexed under COVID-19; 466 are open to participants now.
This study's planned enrollment of 345 is above the median of 268 across 3,208 observational studies indexed under COVID-19.
Browse COVID-19 studies →Hellenic Institute for the Study of Sepsis is the lead sponsor of 32 studies on the registry; 7 are open to participants now.
Counted across the registry records on this site, refreshed daily.
POINT will include patients who have participated in the studies ESCAPE, SAVE, SAVE-MORE and SAVE-LONG. For these patients blood samples and clinical data are already available (Baseline - Year 0 from ESCAPE, SAVE \& SAVE-MORE and Year 1 from SAVE-LONG).
POINT needs to enroll three groups of patients (selected by the existing biobank mentioned above, based on the inclusion and exclusion study criteria) to cover the magnitude of the spectrum of COVID-19:
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Group A (comparators)
Group B (patients with ΝΟ dysfunction)
Group C (patients with dysfunctions)
Exclusion Criteria:
Group A (comparators)
Group B (patients with ΝΟ dysfunction)
Group C (patients with dysfunctions)
Medical history of any of:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
COPD
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Comparators without medical history of acute infection by SARS-CoV-2.
Other: Blood samples · Other: Six-minute walk test, Spirometry, HRCT, Heart ultrasound, Completion of questionnaires of symptoms
Patients fully recovered by acute COVID-19 who did not present any acute organ injury during acute infection by SARS-CoV-2.
Other: Blood samples · Other: Six-minute walk test, Spirometry, HRCT, Heart ultrasound, Completion of questionnaires of symptoms
Patients who presented signs of lung, heart, and kidney dysfunction during acute infection by SARS-CoV-2.
Other: Blood samples · Other: Six-minute walk test, Spirometry, HRCT, Heart ultrasound, Completion of questionnaires of symptoms
Blood sampling for proteomics and transcriptomics, suPAR measurement \& isolation and stimulation of peripheral blood mononuclear cells, eGFR, serum creatinine, cystatin c \& urea
Spirometry for forced expiratory volume in the first, second, total lung capacity and diffusion capacity of carbon monoxide.
The incidence of any organ dysfunction during the first 48 months among patients of group C compared to group B
This is a composite endpoint which includes the development of chronic failures of at least one of lung, heart and/or kidneys
Time frame: From enrollment to Month 48
The incidence of any organ dysfunction during the first 48 months among patients of group C compared to group A.
This is a composite endpoint which includes the development of chronic failures of at least one of lung, heart and/or kidneys.
Time frame: From enrollment to Month 48.
The incidence of any organ dysfunction during the first 48 months among patients of group B compared to group A.
This is a composite endpoint which includes the development of chronic failures of at least one of lung, heart and/or kidneys.
Time frame: From enrollment to Month 48.
The incidence of chronic lung failure during the first 48 months among patients of group C compared to group B.
Time frame: From enrollment to Month 48.
• The incidence of chronic heart failure during the first 48 months among patients of group C compared to group B.
Time frame: From enrollment to Month 48.
• The incidence of chronic renal disease during the first 48 months among patients of group C compared to group B.
Time frame: From enrollment to Month 48.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Hellenic Institute for the Study of Sepsis